Evotec SE (NASDAQ: EVO) reported Q3 Revenue for the quarter at EUR535.1 million.

Guidance for full-year 2025 confirmed

Group revenues expected in the range of € 760 - 800 m (2024: € 797.0 m)

R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.9 m)

Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m)

Outlook 2028

Group revenues CAGR 2024-2028 targeted to be in a range of 8 - 12%

Adjusted EBITDA margin 2028 expected to be above 20%

For earnings history and earnings-related data on Evotec SE (EVO) click here.